<table border="single" id="id_4a5ae9e9-4635-4f0b-9fc7-4b0732297438" width="464" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_8c0057b4-146a-4e39-9a94-d9949d878aec"> Table 9:   Results of Drug Interaction Studies with Didanosine: Effects of Coadministered                  Drug on didanosine Plasma AUC and C<sub>max</sub> Values</caption>
<col width="32.1%"></col>
<col width="27.6%"></col>
<col width="6.9%"></col>
<col width="16.2%"></col>
<col width="17.2%"></col>
<tfoot id="id_d58d3a6c-f63a-4d04-b2ae-f075a70b1012">
<tr>
<td align="left" colspan="5" stylecode="Botrule" valign="top">↑  Indicates increase.<br/>↓  Indicates decrease.<br/>↔ Indicates no change, or mean increase or decrease of less than 10%.</td>
</tr>
</tfoot>
<tbody>
<tr id="id_22a0ec18-0a82-4bf3-a08b-569878c0516c">
<td align="left" colspan="3" stylecode="Toprule" valign="top"></td>
<td align="center" colspan="2" stylecode="Botrule" valign="top">
<paragraph>
<content stylecode="bold">% Change of Didanosine</content>
</paragraph>
<content stylecode="bold">Pharmacokinetic Parameters<footnote id="id-4ac43b6c-d627-400b-b068-6e11aea156a4">The 90% confidence intervals for the percent change in the pharmacokinetic parameter are displayed.</footnote>
</content>
</td>
</tr>
<tr id="id_44fd74dd-8133-47b0-9d8d-e6fff458f761">
<td align="left" colspan="3" stylecode="Botrule" valign="top">
<content stylecode="bold">             Drug                                      Didanosine Dosage                       n        </content>
</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>
<content stylecode="bold">AUC of Didanosine</content>
</paragraph>
<content stylecode="bold">(90% CI)</content>
</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>
<content stylecode="bold">C<sub>max</sub> of Didanosine</content>
</paragraph>
<content stylecode="bold">(90% CI)</content>
</td>
</tr>
<tr id="id_847698dc-3a70-4c9a-9e51-44d56d253710">
<td align="left" stylecode="Botrule" valign="top">
<paragraph>tenofovir,<footnote id="id-3702ccd3-c2dd-482a-94a8-cb08cf7f2700">All studies conducted in healthy volunteers at least 60 kg with creatinine clearance of at least 60 mL/min.</footnote>, <footnote id="id-ec7295e7-5eb4-4bd2-bf6c-b679b18a4253">Tenofovir disoproxil fumarate.</footnote> 300 mg</paragraph>
<paragraph>  once daily with a light meal<footnote id="id-f68c9d98-2c5d-409c-a4d7-c63acbcbc670">373 kcalories, 8.2 grams fat.</footnote>
</paragraph>
<paragraph>tenofovir, <footnoteref idref="id-3702ccd3-c2dd-482a-94a8-cb08cf7f2700"></footnoteref>, <footnoteref idref="id-ec7295e7-5eb4-4bd2-bf6c-b679b18a4253"></footnoteref> 300 mg</paragraph>
<paragraph>  once daily with a light meal<footnoteref idref="id-f68c9d98-2c5d-409c-a4d7-c63acbcbc670"></footnoteref>
</paragraph>
<paragraph>tenofovir, <footnoteref idref="id-3702ccd3-c2dd-482a-94a8-cb08cf7f2700"></footnoteref>, <footnoteref idref="id-ec7295e7-5eb4-4bd2-bf6c-b679b18a4253"></footnoteref> 300 mg</paragraph>
<paragraph>  once daily with a light meal <footnoteref idref="id-f68c9d98-2c5d-409c-a4d7-c63acbcbc670"></footnoteref>
</paragraph>
<paragraph>
<content stylecode="bold">methadone</content>, chronic</paragraph>
maintenance dose</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>400 mg single dose</paragraph>
<paragraph>fasting 2 hours before tenofovir</paragraph>
<paragraph>400 mg single dose</paragraph>
<paragraph>with tenofovir and a light meal</paragraph>
<paragraph>200 mg single dose</paragraph>
<paragraph>with tenofovir and a light meal</paragraph>
<paragraph>250 mg single dose</paragraph>
<paragraph>with tenofovir and a light meal</paragraph>
<paragraph>325 mg single dose</paragraph>
<paragraph>with tenofovir and a light meal</paragraph>
400 mg single dose</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>26</paragraph>
<paragraph>25</paragraph>
<paragraph>33</paragraph>
<paragraph>33</paragraph>
<paragraph>33</paragraph>
15, 16<footnote id="id-4fa6f86a-96ce-4f01-9713-934c383a5b74">Comparisons are made to historical controls (n=148, pooled from 5 studies) conducted in healthy subjects. The       number of subjects evaluated for AUC and C<sub>max</sub> is 15 and 16, respectively.</footnote>
</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>↑ 48%</paragraph>
<paragraph>(31, 67%)</paragraph>
<paragraph>↑ 60%</paragraph>
<paragraph>(44, 79%)</paragraph>
<paragraph>↑ 16%</paragraph>
<paragraph>(6, 27%) <footnote id="id-9cffa8a3-5552-42e7-a378-ab8b96e1d6b9">Compared with didanosine 250 mg administered alone under fasting conditions.</footnote>
</paragraph>
<paragraph>↔</paragraph>
<paragraph>(-13, 5%)<footnote id="id-d2de8402-6cc7-455d-a4e8-638a7cb71c1d">Compared with didanosine 400 mg administered alone under fasting conditions.</footnote>
</paragraph>
<paragraph>↑ 13%</paragraph>
<paragraph>(3, 24%)<footnoteref idref="id-d2de8402-6cc7-455d-a4e8-638a7cb71c1d"></footnoteref>
</paragraph>
<paragraph>↓ 17%</paragraph>
(-29, -2%)</td>
<td align="center" stylecode="Botrule" valign="top">
<paragraph>↑ 48%</paragraph>
<paragraph>(25, 76%)</paragraph>
<paragraph>↑ 64%</paragraph>
<paragraph>(41, 89%)</paragraph>
<paragraph>↓ 12%</paragraph>
<paragraph>(-25, 3%)<footnoteref idref="id-9cffa8a3-5552-42e7-a378-ab8b96e1d6b9"></footnoteref>
</paragraph>
<paragraph>↓ 20%</paragraph>
<paragraph>(-32, -7%)<footnoteref idref="id-d2de8402-6cc7-455d-a4e8-638a7cb71c1d"></footnoteref>
</paragraph>
<paragraph>↓ 11%</paragraph>
<paragraph>(-24, 4%)<footnoteref idref="id-d2de8402-6cc7-455d-a4e8-638a7cb71c1d"></footnoteref>
</paragraph>
<paragraph>↓ 16%</paragraph>
(-33, 4%)</td>
</tr>
</tbody>
</table>